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addition, Tc17 cells do not produce IL-
17 exclusively, as most CD8þ IL-17þ
cells also secrete TNF-a and about half
produce IFN-g along with IL-17 (Ortega
et al., 2009), a feature that can also be
attributed to MAIT cells.
In the light of the information pre-
sented here, it is important to determine
whether the IL-17þCD8þ T cells in
psoriatic skin are conventional MHC
class I–restricted T cells or belong to
the MAIT subset. In this paper Teunissen
et al. (2014) demonstrate that, although
MAIT cells are found in psoriatic
skin, they represent only a proportion of
IL-17A-expressing CD8þ T cells
and that the majority of Tc17 clones
derived from psoriatic epidermis are
conventional T cells. In addition, the
investigators demonstrate that the
frequency of Tc17 cells in peripheral
blood correlates with disease severity,
although they did not take the next step
of determining whether the cells belong
to the MAIT subset rather than being
conventional CD8þ T cells. Taken
together, these data suggest that MAIT
cells are unlikely to have a major role
in the pathogenesis of psoriasis and,
instead, focus the spotlight back on
conventional Tc17 cells as the critical
CD8þ T-cell population in psoriasis
pathogenesis. This, along with other
evidence supporting the role of CD8þ
T cells in psoriasis (Elder et al., 2010),
indicates that these cells may have been
either selectively recruited to or expan-
ded in the epidermis of psoriatic skin.
Expansion might occur after recogni-
tion of antigens in the context of MHC
class I, with HLA-Cw*0602 being most
likely the restriction element in a large
proportion of patients with psoriasis
(Nair et al., 2006). This is a relatively
unexplored avenue of research in
psoriasis, but addressing the nature of
the antigen specificity of conventional
CD8þ T cells in psoriasis is very attrac-
tive. It holds considerable promise
because it is the most likely approach
to eventually ‘‘cure’’ psoriasis.
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Manipulated Microenvironment in
Human Papilloma Virus–Infected
Epithelial Cells: Is the CD40–CD154
Pathway Beneficial for Host or Virus?
Takatoshi Shimauchi1 and Vincent Piguet1
In this issue, Tummers et al. (2014) demonstrate that high-risk human papilloma
viruses (hrHPVs) attenuate the magnitude of responses to CD40 ligation and the
epithelial cells’ (ECs) capacity to attract leukocytes. These results suggest that
hrHPVs can escape from host immune surveillance by modulating pro-inflamma-
tory responses in infected ECs, resulting in persistent infections and potential
carcinogenesis.
Journal of Investigative Dermatology (2014) 134, 2866–2868; doi:10.1038/jid.2014.357
The human papilloma virus (HPV) is
a non-enveloped double-stranded DNA
virus that infects human epithelial
tissues, including skin, anogenital epi-
thelia, and oral cavity mucosa. In parti-
cular, hrHPVs, including HPV16 and
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HPV18, are associated with cervical
cancer, which is the second most com-
mon cancer in women.
To eliminate viral invasion, skin-
resident cells, including keratinocytes,
Langerhans cells (LCs), dermal dendritic
cells (DCs), and macrophages, express
many pattern-recognition receptors such
as C-type lectin receptors, Toll-like
receptors (TLRs), nucleotide-binding
oligomerization domain–like receptors,
retinoic acid–inducible gene I–like
receptors (RLRs), and cytosolic DNA
sensors, which can detect pathogen-
associated molecular patterns of the
invading viruses, which, in turn, activate
anti-viral immune responses (Kawamura
et al., 2014). Because keratinocytes in
the basal layer of the epithelia are the
major targets of HPV, the innate and
adaptive immune responses by ECs have
important roles in eliminating HPV. For
instance, ECs express several TLRs on
their cell surfaces (TLR-1, TLR-2, TLR-5,
TLR-6, and TLR-10) or in endosomes
(TLR-3 and TLR-9), and their activation
initiates signaling pathways that result in
both innate and adaptive immune res-
ponses. In particular, TLR-9 recognizes
double-stranded CpG-rich DNA, and the
activation of TLR-9 in ECs results in the
production of cytokines and chemokines
such as tumor necrosis factor-a, IL-8,
MCP-1, MIP-3a, MIG, and IFN-1(Lebre
et al., 2007). The consequent pro-
inflammatory microenvironments within
the epithelia lead to the recruitment of
DCs, LCs, T cells, and Natural killer
cells, which, in turn, help eliminate
HPV-infected keratinocytes.
However, HPV can also escape from
host immune surveillance by downregu-
lating this pro-inflammatory response
in ECs using two principal oncoproteins
E6 and E7 (Li et al., 1999; Um et al.,
2002). In recent studies, investigators in
this same laboratory have demonstrated
that hrHPV dampens a network of genes
encoding chemotactic, pro-inflamma-
tory, and anti-microbial cytokines in
ECs that is activated by TLR-3, protein
kinase R, RLRs, and melanoma differen-
tiation–associated gene 5 (Karim et al.,
2011). They have also demonstrated
mechanisms by which hrHPV inhibits
these responses in ECs. hrHPV can
upregulate a cellular protein called
ubiquitin carboxyl–terminal hydrolase
L1 (UCHL1), which suppresses activation
of signals downstream of the pathogen-
recognition receptor, leading to reduced
Clinical Implications
 Activation of epithelial cells (ECs) via CD40 induces immune-related, anti-
proliferative, and anti-apoptotic genes, and the capacity to cause the
migration of immune cells.
 High-risk human papilloma viruses (hrHPVs) attenuate the magnitude of
responses to CD40 ligation, including a reduced capacity of ECs to attract
immune cells.
 The CD40–CD154 pathway has an important role in protective epithelial
immune responses to infection.
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Figure 1. Potential immune responses in endothelial cells (ECs) via CD40–CD154 activation. INF-g-induced CD40-expressing ECs can interact with activated,
CD40 ligand (CD154)–expressing T lymphocytes. Engagement of CD40 causes conformational changes that recruit adapter molecules known as TRAFs. TRAFs
recruit TRAF-interacting kinases and activate the NF-kB, p38/MAPK, and JNK pathways. CD40 signaling induces the production of pro-inflammatory cytokines and
chemokines required for the migration of immune cells such as LCs, DCs, and leukocytes, resulting in the establishment of a pro-inflammatory microenvironment.
The high-risk human papilloma virus (hrHPV) interferes with CD40 signaling and attenuates these responses. CD40 ligation also induces the activation of Ras and
PI3K, leading to the production of VEGF, which can promote angiogenesis in the dermis. DCs, dendritic cells; JNK, c-JUN-NH2-kinase; LCs, Langerhans cells;
NF-kB, nuclear factor-kB; p38/MAPK, p38/mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; TRAF, tumor necrosis factor receptor associated
factors; VEGF, vascular endothelial growth factor.
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transcription factor activation and down-
stream gene expression (Karim et al.,
2013). In addition, these findings
suggest an important role for ECs as
initiators of immune responses against
HPV and as a link to the adaptive
immune response.
In the current issue of JID, Tummers
et al. (2014) demonstrate that IFN-g-
induced CD40-expressing ECs react in
a coordinated way to CD40 ligation
with the induction of immune-related
genes by using genome-wide expression
profiling. They also confirm that
IL-8 and RANTES, produced by CD40-
ligated ECs, have a capacity to
cause immune cell migration. hrHPVs
attenuate the magnitude of the
response to CD40 ligation and the ECs’
capacity to attract immune cells.
UCHL1 may explain the mechanisms
of impaired CD40 signaling in rhHPV-
infected ECs.
A similar in vitro study has shown
previously that CD40 ligation can
induce the production of RANTES,
MCP-3, and IP-10 in both nonmalignant
and malignant HPV-positive cervix cell
lines when stimulated with IFN-g
(Altenburg et al., 1999). In this regard,
a key finding in Tummers et al. (2014) is
that CD40 ligation of ECs can recruit
lymphocytes, as well as myeloid cells,
and this process is attenuated by hrHPV
infection (Figure 1). This is an important
finding because it was previously
unclear whether HPV infection could
inhibit the migration of immune cells
into the ECs in a human model.
CD40 is expressed on ECs in a wide
variety of tissues. Its expression and
function in these cells contribute to
their role as immune effectors within
local microenvironments (Dugger et al.,
2009). Engagement of epithelial CD40
activates these cells and results in the
release of pro- and anti-inflammatory
mediators (Dugger et al., 2009). How-
ever, CD40 is also found in some tumor
cells, and engagement via the CD40
ligand can lead to the production of
vascular endothelial growth factor
(VEGF) and fibroblast growth factor,
resulting in the promotion of angio-
genesis (Bergmann and Pandolfi,
2006; Figure 1). These two functions of
CD40, promoting immune responses
and promoting angiogenesis, have
opposite effects on the growth of tumors
(Bergmann and Pandolfi, 2006). In vivo
studies have shown that CD40 expres-
sion is significantly higher in cervical
carcinomas than in cervicitis and in the
normal cervix, and CD40 ligand was
detected on a subpopulation of tumor-
infiltrating lymphocytes (Altenburg
et al., 1999; Huang et al., 2011). In
addition, the expression of CD40 is also
correlated significantly with HPV, VEGF
expressions, and microvessel density
(Huang et al., 2011). Thus, in the case
of HPV-infected cervical carcinoma,
there is a possibility that the CD40–
CD154 pathway contributes to angio-
genesis via VEGF production, resulting
in tumor progression and metastasis.
Therefore, the situation in vivo is even
more complex, and it is intriguing to
question whether activation of the
CD40–CD154 pathway in HPV-infected
ECs is beneficial for host immune sur-
veillance and/or whether it promotes
HPV carcinogenesis.
Two prophylactic HPV vaccines
(Gardasil and Cervarix) are currently
available and have been shown in
clinical trials to have a high efficacy
for the prevention of infection and asso-
ciated diseases attributed to HPV types
targeted by the vaccine. However, both
vaccines provide no protection for
women already infected with HPV16
and 18 serotypes (Nikolic and Piguet,
2010). The administration of adjuvants
such as TLR agonists, including lipo-
polysaccharide (TLR-4 agonist), 3 M-002
(TLR-8 agonist), resiquimod (TLR-7 and
8 agonist), and oligodeoxinucleotide
(TLR-9 agonist), shows promise for the
elimination of HPV from ECs in in vitro
studies or in a mouse model (Amador-
Molina et al., 2013). However, as shown
by the investigators and their research
groups, pro-inflammatory immune
responses against HPV are downregu-
lated in HPV-infected ECs (Karim et al.,
2011; Karim et al., 2013; Tummers et al.,
2014). Thus, new adjuvants or other
molecules that can improve the micro-
environment surrounding HPV infection
will be beneficial in treating HPV. In
order to confirm a potential use for CD40
ligand, either alone or in combination
with other adjuvants to treat HPV, pre-
clinical animal models will be required.
Results from such studies may have
important implications for the treatment
of HPV-associated diseases.
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